Winning The Battle Against HIV-1: (MPTV-x , HAART-x) / (MPTV-x , Mega-HAART-x) - Couples Formed of a Multivalent-Polivalent-Therapeutic-Vaccine
(MPTV-x) and Its Corresponding HAART-x , or Mega-HAART-
Regimen , Respectively.
Iosif Secasan
Department of Urologic Surgery
Spitalul Judetean Resita / The Hospital of Resita
RO-1700, Resita
Dan I. Pop
Data International SRL
Str. Horia, Nr.6, Bl.6, Et.10, Ap.39 Resita-1700, RO-1700, Romania
Phone: 0040-722-940299 E-mail : danpop77@yahoo.com
Ciprian C. Secasan
Department of Microbiology / Department of Urologic Surgery
Spitalul Judetean Resita / The Hospital of Resita
RO-1700, Resita
Abstract : This article presents an entirely new theory and practical solution to eradicate HIV-1, based on HIV-1's ability and need to mutate under HAART-x / Mega-HAART-x drugs pressure, and on the sinergetical scissoring effect on HIV-1 of (MPTV -x , HAART-x) - couples and (MPTV-x , Mega-HAART-x)-couples, which are formed of :
1. a multivalent-polyvalent-therapeutic-vaccine (MPTV -x) , made of whole-killed HIV-1 (or of particular parts of HIV-1) bearing on its genome (biochemical structure) the resistance-
mutations-pattern (RMP-x) that would be induced by the following , to come HAART-x or Mega-HAART-x regimen
and of
2. the respective, corresponding HAART-x or Mega-HAART-x regimen, respectively.
Key Words :
HAART (highly-active-anti-retroviral-therapy), HAART-x regimen, Mega-HAART-x regimen, point-mutations (PM), resistance-mutations-loci (RML-x), resistance-mutations-sites (RMS-x), resistance-mutations-pattern (RMP-x-),
multivalent-polyvalent-therapeutic-vaccine (MPTV -x), (MPTV -x, HAART-x)-couples,
(MPTV-x,Mega-HAART-x)-couples, drug-resistant-virus(DRV) , drug-sensitive-virus (DSV);
1. Hahn B.H. , Robertson D.L. , McCutchan F.E. , Sharp P.M. , Recombination and diversity of HIV: implications for vaccine development. Neuvieme Colloque Des Cent Gardes ,
1994, 87-94 ;
2. Robertson D.L. , Sharp P.M. , McCutchan F.E. , Hahn B.H. , Recombination in HIV-1, Nature 1995 : 374 :124-126;
3. Robertson D.L. , Hahn B.H. , Sharp P.M. , Recombination in Aids viruses, J.Mol.Evolution , 1995, 40, 249-259;
4. Sharp P.M., Robertson D.L., Hahn B.H. , Cross - species transmission and recombination of ' AIDS ' viruses. , Phil. Trans. R. Soc., London B , 1995, 349 : 41-47;
5. M. L. Kalish et al, Recombinant Viruses and Early Global HIV-1 Epidemic, Emerging Infectious Diseases, Vol.10, No.7, July 2004;
6. I.S. Secasan, D.I. Pop , Fighting HIV with HIV, Medical Hypotheses,1998 Jan;50(1):39-42 Churchill-Livingstone, ISSN 0306-9877;
7. Young, S.D., et al. L870,810: Discovery of a potent HIV integrase inhibitor with potential clinical utility, Presented at The XIV International AIDS, Conference, Barcelona, Spain.
8. http://www.adventrx.com/products/antiv_eradicaide.htm
9. http://www.imnr.com : The Immune Response Corporation, Inc. web-site
10. http://www.affymetrix.com/index.affx
11. Iosif Secasan, Dan I. Pop, Ciprian C. Secasan: Potentially New And Innovative Treatments For Superficial, Muscle-Invasive, And Metastatic Transitional Cell Carcinoma (TCC) Of The Bladder. The Internet Journal of Oncology. 2005. Volume 2 Number 2.